Hepatocyte growth factor (HGF), an antimitogenic factor for HepG2 cells, increased mRNA and protein levels of UGT1A1 and CYP2B6 as well as the endogenous cycline-dependent kinase (CDK) inhibitors p16, p21, and p27 in HepG2 cells, but not HuH6, Caco2, or MCF7 cells.
Introduction
The constitutive androstane receptor (CAR, NR1I3) was originally characterized as a nuclear hormone receptor that interacts with a subset of retinoic acid response elements (Beas et al., 1994) . CAR and pregnane X receptor (PXR, NR1I2) have been recognized as xenobiotic-sensing nuclear receptors that transcriptionally regulate the expression of genes of phase I, II, and III metabolic enzymes and transporters involved in the metabolism and elimination of endogenous and exogenous substances such as bilirubin, steroid hormones, and xenobiotics (Timsit and Negishi, 2007) . UDP-glucuronosyltransferase, UGT1A1, plays a critical role in the detoxification of potentially neurotoxic bilirubin by conjugating it with glucuronic acid for excretion in bile (Ostrow and Murphy, 1970) and conjugates drugs and other xenobiotics (Radominska-Pandya et al., 1999; Tukey and Strassburg, 2000) . We identified a phenobarbital -responsive enhancer module at -3499/-3210 from the transcription start site of UGT1A1, gtPBREM (Sugatani et al., 2001) , and demonstrated that the gtNR1 (-3382/-3367) within gtPBREM plays a central role in the expression of UGT1A1 mediated by both CAR and PXR (Sugatani et al., 2005a) . In addition, we demonstrated that HNF1α bound to the proximal promoter motif not only enhances the basal reporter activity of UGT1A1 including the distal (-3570/-3180) and proximal (-165/-1) regions, but also influences the transcriptional regulation of UGT1A1 by CAR, PXR, glucocorticoid receptor (GR), and arylhydrocarbon receptor (AhR) to markedly enhance reporter activities .
Previously, we demonstrated that CAR expression changes during the cell cycle in HepG2 and SW480 cells and CAR protein accumulates during G1 in both cells ).
Here we found that UGT1A1 and CYP2B6 began to accumulate in late mitosis, preceding the CAR's accumulation in the nucleus, and remained at high levels during G1 coinciding with CAR's accumulation. Klinger et al. (1987) 
demonstrated that a transient decrease in CYPs
This article has not been copyedited and formatted. The final version may differ from this version. (Aubrecht et al., 1995) . However, it remains to be fully elucidated how the expression of drug-metabolizing enzymes including UGT1A1 and CYP2B6 is regulated by cell signals associated with cell-cycle progression.
CAR is predominantly expressed in the liver and is found in the cytoplasm of normal mouse hepatocytes in the absence of stimuli such as drug-treatment (Kawamoto et al., 1999) .
CAR is activated by phenobarbital (PB) and PB-like inducers such as 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), that do not bind it directly but activate a signal transduction pathway, resulting in the translocation of CAR from the cytoplasm to the nucleus (Kawamoto et al., 1999) . Koike et al. (2008) demonstrated that ERK is an endogenous signal retaining CAR in the cytoplasm in mouse primary hepatocytes, showing that (1) hepatocyte growth factor (HGF) effectively repressed the induction of endogenous Cyp2b10 gene by PB and 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in mouse primary hepatocytes, (2) HGF increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 in the cytosol, decreasing the TCPOBOP-induced nuclear accumulation of CAR, and (3) U0126 dephosphorylated ERK1/2 and increased nuclear CAR accumulation leading to enhanced CAR-regulated promoter activities. While HGF is a potent mitogen for hepatocytes, it is an antimitogenic factor for some tumor cell lines including HepG2; HGF has been demonstrated to induce p16 and p21 expression and decrease cyclin-dependent kinase (CDK) 2 activity, leading to inhibition of cell growth (Shima et al., 1998; Han et al., 2005) . p16 and p21, which are endogenous CDK2/CDK4 inhibitors, are involved in regulating cell cycle progression. Here we found that HGF treatment increased the expression of UGT1A1 and CYP2B6 in HepG2 cells, This article has not been copyedited and formatted. The final version may differ from this version. even when CAR levels decreased both in the cell and in the nucleus. A recent study by Lin et al. (2008) demonstrated that inhibition of CDKs by roscovitine leads to activation of PXR-mediated CYP3A4 gene expression and that CDK2 negatively regulates the activity of PXR in HepG2 cells.
Thus, in the present study, we investigated the cell signaling involved in the HGF-stimulated expression of UGT1A1 and CYP2B6 in HepG2 cells in order to examine whether CDKs participate in the cell-cycle-dependent expression of UGT1A1 and CYP2B6.
Materials and Methods
Materials -U0126, U0124, LY294002, SB203580, SP600125, roscovitine, SU9516, and the CDK inhibitor p35 were purchased from Calbiochem (Darmstadt, Germany). EGF and platelet-derived growth factor (PDGF) were obtained from Sigma-Aldrich (St. Louis, MO).
Histone H1 and adenosine-S-triphosphate (ATP) were from Roche Diagenostics (Mannheim, Germany). All other chemicals and solvents were of analytical grade and obtained from commercial sources.
Cell culture conditions and treatments -HepG2 and HuH6 human hepablastoma cells, Caco2 human colon carcinoma cells, and MCF7 human breast adenocarcinoma cells from RIKEN BioResource Center (Ibaraki, Japan) and SW480 human colon cancer cells from the American Type Culture Collection (1 x 10 5 cells/ml) were cultured in Dulbecco's modified Eagle's medium (DMEM, HepG2, HuH6, Caco2, and MCF7 cells) and RPMI1640 medium (SW480 cells) with 10% fetal calf serum (FCS) and antibiotics (100 μg of streptomycin and 10 U of penicillin/ml) or DMEM-Ham's F12-serum-free medium supplemented with 2 mM glutamine, 15 mM HEPES, 5 μg/ml insulin, 10 μg/ml bovine transferine, 10 ng/ml Na 2 SeO 3 , 2 μg/ml aminolevulinic acid, 25 mM glucose, 0.5 mg/ml linoleic acid-alubumin, 1 mM pyruvate with or without 100 ng/ml This article has not been copyedited and formatted. The final version may differ from this version. At 24 h after transfection, cells were given fresh medium and further transfected with the siRNA duplexes for an additional 24 h unless stated otherwise.
Quantitative reverse transcription -PCR -Total RNA was extracted using TRIZOL reagent from Invitrogen, and cDNAs were synthesized with a PrimeScript RT reagent kit (Takara Bio, Otsu, Japan) according to the directions. cDNA synthesized from 100 ng of total RNA was subjected to quantitative real-time PCR with Premix Ex Taq or SYBR Premix ExTaq (Takara Bio) for UGT1A1 (NM_000463), CYP1A1(NM_000499), CYP2B6 (NM_000767), CYP3A4
(NM_017460), CAR (NM_005122), PXR (NM_022002), retinoid X receptor (RXR, NM_002957), AhR (NM_001621), p16 (NM_000077), p21 (NM_000389), p27 (NM_004064), CDK2 (NM_001798), and CDK4 (NM_000075), as described previously ).
This article has not been copyedited and formatted. The final version may differ from this version. phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mM benzamidine, 1 μg/ml aprotinin, and 1 μg/ml leupeptin at 4 o C. The lysates were centrifuged at 110,000 g for 10 min.
Nuclear extracts were prepared using a nuclear extract kit (Active Motif). Microsomal proteins were prepared as described previously (Sugatani et al., 2004) . The protein concentrations were determined by the Bradford assay (Bio-Rad). Western blotting was performed as described . Briefly, nuclear extracts, microsomal proteins, or cell lysates (50 μg) were resolved on 12.5% SDS-polyacrylamide gels and the proteins were transferred electrophoretically Research)] and visualized with an enhanced chemiluminescence system (GE Healthcare UK Ltd., Little Chalfont, England).
In vitro kinase assay -CDK2 kinase assays were performed as described previously (Walter et al., 2002) . Cell lysates were cleared by centrifugation, and equal amounts of protein in the cell extracts (200 μg) were immunoprecipitated with 2 μg of anti-CDK2 antibody for 3 h at 4 o C.
Precipitated immune complexes were washed three times with the cell lysis buffer and twice with a kinase buffer [50 mM Tris-HCl, (pH 7.5) containing 10 mM MgCl 2 , 1 mM dithiothreitol, 20 mM EGTA, 10 mM β-glycerophoshate, 0.1 mM sodium orthovanadate, and 1 mM NaF].
Kinase reactions were performed in 10 μl of the kinase buffer containing 25 μg of histone H1, 100 μM ATP, and 0.37 MBq of [γ- Statistics -Values are expressed as the mean ± standard error. All data were analyzed using a one-way analysis of variance. The statistical significance of differences between groups was analyzed using the ANOVA or an unpaired t-test. The level for statistically significant differences was set at p<0.05.
Results

Expression of UGT1A1, CYP2B6, and cyclin kinase inhibitors p16, p21, and p27 during HGF-induced HepG2 growth inhibition. While HGF is a potent mitogen for many types of cells
This article has not been copyedited and formatted. The final version may differ from this version. Whereas HGF downregulated the expression of CYP isozymes in human hepatocytes (Donato et al., 1998) , its function in tumor cells remains to be resolved. To assess the effects of growth factor on the expression of drug-metabolizing enzymes in tumor cells, the response to HGF was compared between two opposite responding types of human hepatoblastoma cells, HepG2 and
HuH6 (Shima et al., 1998) (Fig. 1B) . The mRNA expression of CDK inhibitors (p16, p21, and p27) was induced 24 h after treatment with HGF in HepG2 cells, but the levels did not change in HuH6 cells. While the mRNA level of CAR decreased in HepG2 cells, the mRNA levels of UGT1A1 and CYP2B6 increased (Fig. 1B) . In contrast, in Caco2 and MCF7 cells after 24 h of culture with HGF, neither the mRNA levels of UGT1A1 and CYP2B6 nor the mRNA levels of p16, p21, and p27 were increased (data not shown).
To investigate the cell signaling specifically required for stimulation by growth factors, effects of growth factors on the expression of drug-metabolizing enzymes and nuclear receptors in serum-free-medium were determined (Fig. 2) . The mRNA level of UGT1A1 was increased after treatment with HGF and EGF but not PDGF, whereas the mRNA levels of CAR and PXR but not RXR and AhR were decreased (Fig. 2) . The mRNA level of CYP2B6 was increased by HGF. The protein levels of UGT1A1 and CYP2B6 but not CPR were increased, whereas that of CAR in the nucleus was decreased and those of PXR and RXR remained largely unchanged after HGF-treatment ( Fig. 2II and 2III ). In serum-free-medium, the production of p16, p21, and p27
proteins was induced 1 h after treatment with HGF, and the expression of p21 and p27 sustained for at least 24 h, consistent with the phosphorylation of ERK1/2 (Fig. 3A) . Next, to assess the signaling pathway of UGT1A1 and CYP2B6 expression after HGF treatment, we examined the This article has not been copyedited and formatted. The final version may differ from this version. (negative control) decreased the mRNA levels of UGT1A1 and CYP2B6 in HGF-treated cells (Fig. 3B) , whereas the mRNA levels of CAR but not PXR, RXR, or AhR increased in the cells; the mRNA levels of CAR increased to 2.0 + 0.3-and 1.5 + 0.3-fold of the control by U0126 in the absence and presence of HGF, respectively (data not shown). Similarly, U0126 decreased the mRNA levels of UGT1A1 in EGF-treated cells cultured in serum-free-medium (data not shown). The HGF-induced expression of endogenous cyclin kinase inhibitors (p16, p21, and p27) was also suppressed by U0126 (Fig. 3A) . These results suggest the ERK pathway to be involved in the effect of growth factors such as HGF and EGF on UGT1A1 expression as well as the induction of p16, p21, and p27 expression. On the other hand, LY294002 and SP600125
increased the mRNA levels of UGT1A1 and CYP2B6 in HGF-treated cells compared with those in the control cells, suggesting PI3-kinase and JNK to be involved in the HGF-induced expression of UGT1A1 and CYP2B6 in HepG2 cells.
Cyclin kinase inhibitors stimulate the expression of UGT1A1, CYP1A1, CYP2B6, and CYP3A4 in
HepG2 cells. To explore whether cyclin kinases are involved in regulating the expression of drug-metabolizing enzymes in human cells, we examined the effects of the CDK inhibitors roscovitine [CDK1, CDK2, and CDK5 inhibitor (Meijer et al., 1999) ], SU9516 [CDK1, CDK2, and CDK4 inibitor (Yu et al., 2002) ], and CDK inhibitor p35 [CDK1 and CDK2 inhibitor (Vermeulen et al., 2002) ] on the expression of UGT1A1, CYP1A1, CYP2B6, and CYP3A4 mRNAs in HepG2 cells. Expression of UGT1A1 mRNA was enhanced by roscovitine, SU9516, and CDK inhibitor p35 in a dose-dependent manner (Fig. 4A ). Roscovitine markedly stimulated the expression of UGT1A1 mRNA and protein, while it slightly stimulated the This article has not been copyedited and formatted. The final version may differ from this version. expression of CYP1A1, CYP2B6, and CYP3A4 mRNAs and proteins (Fig. 4) . Overall, the findings indicated that CDKs were clearly involved in regulating the expression of UGT1A1 and CYP2B6 in HepG2 cells.
Effects of anti-CDK4 siRNA and anti-CDK2 siRNA on induction of UGT1A1 and CYP2B6
expression. Next, to determine whether CDK4 and CDK2, the activities of which were inhibited by p16, p21, and p27, were required for the downregulation of UGT1A1 and CYP2B6 expression, anti-CDK4 siRNA or anti-CDK2 siRNA was introduced into HepG2 and SW480
cells. As shown in Figure 5 , transfection with the anti-CDK4 siRNA dramatically reduced the levels of CDK4 mRNA and protein in HepG2 cells, but was not followed by an increase in mRNA and/or protein levels of UGT1A1, CYP1A1, CYP2B6, and CYP3A4. In contrast, transfection with the anti-CDK2 siRNA in HepG2 and SW480 cells was followed by an increase in mRNA levels of UGT1A1, CYP2B6, and CYP3A4 (Fig. 6) . Furthermore, transfection with the anti-CDK2 siRNA led to stimulated expression of UGT1A1, CYP2B6, and CYP3A4 proteins but not CYP1A1 protein in HepG2 and SW480 cells as well as a decrease in CDK2 protein levels, with the extent of the stimulation by anti-CDK2 siRNA greater in SW480 cells than in HepG2 cells (Fig. 7) .
To determine whether the CDK2 activity was reduced in HepG2 cells after treatment with HGF, we analyzed the extent of phosphorylation of Histone H1 after incubation with the cell lysate. As shown in Figure 8 , the extent of phosphorylation was decreased in HGF-treated cell lysate compared with control lysate, indicating that the CDK2 activity was actually decreased in the HGF-treated HepG2 cells, and that CDK2 activity was required for downregulation of UGT1A1, CYP2B6, and CYP3A4 expression. during the cell cycle, we undertook a detailed analysis of protein levels in synchronously dividing SW480 cells. SW480 cells arrested in S-phase by a double-thymidine block were released into a synchronous cell cycle and sampled every 2 h. Cells completed S-phase in 6 h of their release from the thymidine block and mitosis in 10 h (Fig. 9) . Protein levels of cyclin kinases, cyclins, and drug-metabolizing enzymes in the cell lysate were determined by Western blotting (Fig. 9) .
CDK2 is involved in the cell
As described in the previous study , cyclin A and cyclin B1 protein levels decreased at 12 h to 16 h after release from the thymidine block as cells exited G1. Cyclin D1 was present at very low levels at 0 h after the release and started accumulating. The protein levels of cyclin E1 remained unchanged. CDK4 was present at 0 h to 6 h after release from the thymidine block and started accumulating at 10 h. We found that while the total protein levels of CDK1 and CDK2 remained largely unchanged in the cells after release from the thymidine block for 16 h, the active form of CDK2 (phospho-CDK2) was increased and peaked at 2 h, followed by the active form of CDK1 (phospho-CDK1), which peaked at 4 h. The time-dependent changes in the phospho-CDK2 level matched the time-dependent accumulation of S-phase cells. While the active form of CDK2 (phospho-CDK2) was present at high levels at 2 h to 6 h after release from the thymidine block and these levels dropped at 8 h, UGT1A1 and CYP2B6 were present at very low levels at 0 h to 6 h and started accumulating at 8 h. CYP3A4 was present at very low level at 0 h to 4 h after release from the thymidine block and started accumulating at 6 h, while the protein levels of CPR remained largely unchanged. Moreover, similar cell-cycle-dependent expression of UGT1A1, CYP2B6, and CYP3A4 in HepG2 cells was found as in SW480 cells (data not shown).
Regulatory mechanism of HGF-and roscovitine-stimulated UGT1A1 and CYP2B6 gene expression was different from that of the CYP3A4 gene expression.
Recently, Lin et al. (2008) reported that CDK2 directly phosphorylates PXR and negatively regulates human PXR-mediated This article has not been copyedited and formatted. The final version may differ from this version. Figure 10A and 10B, transfection with anti-CAR siRNA and anti-PXR siRNA reduced the levels of CAR and PXR mRNAs in HepG2 cells, respectively, but did not change the mRNA expression of UGT1A1 stimulated by HGF.
Transfection with anti-CAR siRNA did not change the mRNA levels of UGT1A1 and CYP3A4 stimulated by roscovitine (Supplemental Fig. 2 ). Furthermore, whereas transfection with anti-PXR siRNA reduced the mRNA levels of CYP3A4 stimulated by roscovitine, mRNA levels of UGT1A1 and CYP2B6 after treatment with roscovitine remained similar to those in control cells (Fig. 10C ). These findings suggest that the mechanism to downregulate the expression of UGT1A1 and CYP2B6 gene by HGF and roscovitine may differ from that of CYP3A4 gene.
Discussion
Reduced bilirubin glucuronosyltransferase (UGT1A1) activity is associated with the development of unconjugated hyperbilirubinemia (Crigler-Najjar syndrome and Gilbert's syndrome) (Mackenzie et al., 1997) and increased side effects of drug treatment such as the predisposition of patients to toxicity initiated by SN-38, an active metabolite of the anticancer drug irinotecan (Gange et al., 2002; Tukey et al., 2002) . Understanding the molecular mechanisms of the induction of human UGT1A1 may provide information for the prevention and treatment of unconjugated hyperbilirubinemia and the side effects of drugs. Whereas the proximal 165-bp promoter motif is regulated by HNF1α (Bernard et al., 1999) , the distal 290-bp enhancer module (gtPBREM) of human UGT1A1 is regulated by CAR as a transcription factor in response to phenobarbital treatment (Sugatani et al., 2001) , by PXR as a nuclear receptor responsible for rifampicin-induced activation of gtPBREM (Sugatani et al., 2004) , by GR as a nuclear hormone receptor capable of activating gtPBREM by dexamethasone (Sugatani et al., 2005b) , by the receptor-type transcription factor AhR responsible for p-naphthoflavone-induced activation (Yueh et al., 2003) , and by peroxisome proliferators-activated receptor α (PPARα) responsible for WY-14643 (Senekeo-Effenberger et al., 2007) . The 290-bp gtPBREM is characterized as a composite regulatory element containing the multiple binding sites DR4, gtNR1, DR3, glucocorticoid-response elements (GRE1 and GRE2) for the nuclear receptors CAR, PXR and GR (Sugatani et al., 2001 (Sugatani et al., , 2004 (Sugatani et al., , 2005b , as well as the AhR response element (Yueh et al., 2003) and the PPARα response element (Senekeo-Effenberger et al., 2007) . Notably, the nuclear receptor CAR is essential for regulating UGT1A1 and the CYP2B subfamily by PB and PB-like inducers (Sugatani et al., 2005a; Timsit and Negishi, 2007) .
Hepatocyte growth factor (HGF) is known not only as a potent mitogen for hepatocytes and several types of tumor cells including HuH6, Caco2, and MCF7 cells, but also as an anti-mitogenic factor for some types of tumor cells such as HepG2 cells. In regenerating rat liver induced by extended hepatectomy, the expression of liver-specific genes such as the serum albumin and CYP2B genes has been demonstrated to be suppressed (Kakizaki et al., 2007) .
Moreover, Thasler et al. (2006) demonstrated that an augmenter of liver regeneration, HGF, reduced CAR but not PXR or AhR expression and downregulated basal and induced CYP expression in human hepatocytes in vitro, indicating that growth signals influence hepatic drug metabolism. Downregulation of CYP expression by related factors such as EGF and TGFα has been also observed in humans (Greuet et al., 1997 (Jo et al., 2000) . Shima et al. (1998) found that (1) protein levels of p21 markedly decreased in HGF-treated HuH6 cells, but high levels of p21 were sustained for 24 h after HGF treatment in HepG2 cells, and (2) significant levels of p16 and p27 were observed after 24 h only in HepG2 cells. The induction of p16, p21, and p27 expression by HGF in HepG2 cells is considered to lead to growth inhibition by inhibiting CDKs (CDK2 and CDK4) as reported previously (Shima et al., 1998; Han et al., 2005) . Here we found that (1) and CYP2B6 in HepG2 cells (Fig. 4) . The findings suggested the endogenous CDK inhibitors to be involved in the HGF-induced expression of UGT1A1 and CYP2B6 in HepG2 cells (Fig.   11 ).
In the regulatory network of progression through the mammalian cell-cycle, cyclin D-CDK4 is activated at G1, cyclin E-CDK2 is necessary for G1/S transition, and the activation of CDK4 and CDK2 leads to the nuclear accumulation of cyclin-CDK complexes during G1 (Jaumot et al., 1999) . As shown in Figure 11 , cyclin D1/CDK4/CDK6 and cyclin E/CDK2 complexes cooperate in RB phosphorylation, leading to its inactivation, dissociation of the transcription factor E2F and cell cycle progression (Lundberg et al., 1999) . Thus, to investigate whether CDK plays a key role in the induction of UGT1A1 and CYP2B6 expression, we This article has not been copyedited and formatted. The final version may differ from this version. examined the effect of CDK inhibitors in HepG2 cells. We showed that the expression of UGT1A1 mRNA was induced by roscovitine, SU9516, and CDK inhibitor p35, which all inhibit CDK1 and CDK2 activities (Fig. 4) . Since p16, p21, and p27 repress CDK2 and CDK4 activities, the induction of UGT1A1 expression by roscovitine may be due to the inhibition of CDK2 activity. To confirm whether CDK2 contributes to the induction of UGT1A1 and CYP2B6 expression through cell cycle progression, we deleted CDK2 using siRNA in HepG2 cells expressing the HGF receptor and SW480 cells expressing no HGF receptor (Zeng et al., 2004) . CDK2 deletion resulted in the expression of UGT1A1 and CYP2B6 in both cells, whereas CYP1A1 protein levels were not largely changed in CDK2-deleted cells (Figs. 6 and 7).
In fact, the level of CDK2 activity in HGF-treated cells was decreased (Fig. 8) . CDK2, a key regulator of G1-S cell cycle progression, is activated by Akt-mediated phosphorylation (Maddika et al., 2008) . The inhibition by LY294002 of HGF downstream of the PI3 kinase-Akt signaling pathway led to an increase in the expression of UGT1A1 and CYP2B6 (Fig. 3) , also suggesting the involvement of CDK2 in the HGF-induced expression of UGT1A1 and CYP2B6 in HepG2 cells (Fig. 11) . In contrast, CDK4 deletion using siRNA in HepG2 cells did not lead an increase in the expression of UGT1A1 and CYP2B6 (Fig. 5) . Furthermore, there was a clear dissociation among the expression of activated CDK2 and that of UGT1A1, CYP2B6, and CYP3A4 in cells arrested in S phase by a double-thymidine method and then released into a synchronous cell cycle (Fig. 9) . The findings suggested activated CDK2 to be essential for downregulating the expression of UGT1A1 and CYP2B6. In addition, the inhibition by SP600125 of HGF downstream of the JNK signaling pathway also increased the expression of UGT1A1 and CYP2B6 (Fig. 3) . Since Lu et al. (2009) ( Fig. 11) .
Does CAR or PXR play an essential role in UGT1A1 and CYP2B6 expression in HGF-stimulated HepG2 cells? The CAR protein level not only in the cell lysate but also in the nucleus (Fig. 2) was reduced after HGF treatment. In addition, the suppression of CAR expression using anti-CAR siRNA did not repress the HGF-and roscovitine-induced expression of UGT1A1 (Fig. 10 ). These observations indicate that changes in the expression of CAR did not affect UGT1A1 levels in HGF-and roscovitine-treated HepG2 cells. A recent study by Lin et al. (2008) demonstrated that CDK2 directly phosphorylates PXR and negatively regulates the activity of PXR, leading to the repression of PXR-mediated CYP3A4 expression by roscovitine. However, in the present study, although PXR deletion using siRNA repressed the roscovitine-stimulated CYP3A4 expression in HepG2 cells, it did not affect the HGF-or roscovitine-stimulated expression of UGT1A1 and CYP2B6 (Fig. 10 ). These observations suggest that CDK2 negatively regulates the expression of UGT1A1 and CYP2B6 as well as CYP3A4, but the factor(s) phosphorylated by CDK2, which is involved in the UGT1A1
and CYP2B6 gene expression, may be different from PXR. Data represent the means ± S.E. for 3 experiments. *p<0.05, **p<0.01, ***p<0.001 versus vehicle-treated cells. In C, protein levels in whole-cell lysate after treatment with roscovitine (5 μM) or vehicle were determined by Western blotting. cells cultured for 48 h (control group) were taken as 1. Data represent the means ± S.E.
for 3 experiments. ***p<0.001 versus mock group. were determined by Western blotting with the indicated antibodies. p21, and p27) and induction of UGT1A1 and CYP2B6 during HGF-induced growth inhibition of HepG2 cells is presented.
Supplemental Fig. 1 The proteins in human CYP3A4-expressed microsomes (BD Gentest, Woburn, MA) were detected by Western blotting with anti-CYP3A4 antibody (BD Gentest).
Supplemental 
